Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Where can you publish?
Find journals in COLORADO Profiles by department and year.

Contact Us
If you have any questions or feedback please contact us.

Lisa A Kosmiski

TitleAffiliate - DHHA
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/266-2549

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Vu A, Kosmiski LA, Beitelshees AL, Prigeon R, Sidhom MS, Bredbeck B, Predhomme J, Deininger KM, Aquilante CL. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus. Pharmacotherapy. 2016 Mar; 36(3):252-62.
      View in: PubMed
    2. Vu A, Sidhom MS, Bredbeck BC, Kosmiski LA, Aquilante CL. Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetol Metab Syndr. 2014 Jan 15; 6(1):4.
      View in: PubMed
    3. Kosmiski L, Schmiege SJ, Mascolo M, Gaudiani J, Mehler PS. Chronic starvation secondary to anorexia nervosa is associated with an adaptive suppression of resting energy expenditure. J Clin Endocrinol Metab. 2014 Mar; 99(3):908-14.
      View in: PubMed
    4. Aquilante CL, Wempe MF, Spencer SH, Kosmiski LA, Predhomme JA, Sidhom MS. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pharmacotherapy. 2013 Sep; 33(9):1000-7.
      View in: PubMed
    5. Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Eur J Clin Pharmacol. 2013 Jul; 69(7):1401-9.
      View in: PubMed
    6. Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013 Jan; 75(1):217-26.
      View in: PubMed
    7. McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, Fichtenbaum CJ, Fink H, Sax PE, Libutti DE, Gerschenson M. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013 Feb 15; 207(4):604-11.
      View in: PubMed
    8. Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012 Nov; 52(11):1725-38.
      View in: PubMed
    9. Kosmiski L. Energy expenditure in HIV infection. Am J Clin Nutr. 2011 Dec; 94(6):1677S-1682S.
      View in: PubMed
    10. Kosmiski LA, Scherzer R, Heymsfield SB, Rimland D, Simberkoff MS, Sidney S, Shlipak MG, Bacchetti P, Biggs ML, Grunfeld C. Association of increased upper trunk and decreased leg fat with 2-h glucose in control and HIV-infected persons. Diabetes Care. 2011 Nov; 34(11):2448-53.
      View in: PubMed
    11. Kosmiski LA, Sage-El A, Kealey EH, Bessesen DH. Brown fat activity is not apparent in subjects with HIV lipodystrophy and increased resting energy expenditure. Obesity (Silver Spring). 2011 Oct; 19(10):2096-8.
      View in: PubMed
    12. McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA. Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229. AIDS. 2010 Oct 23; 24(16):2507-15.
      View in: PubMed
    13. Aquilante CL, Kosmiski LA, Zineh I, Rome LC, Knutsen SD. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome. Pharmacotherapy. 2010 Mar; 30(3):236-47.
      View in: PubMed
    14. Kosmiski LA, Ringham BM, Grunwald GK, Bessesen DH. Dual-energy X-ray absorptiometry modeling to explain the increased resting energy expenditure associated with the HIV lipoatrophy syndrome. Am J Clin Nutr. 2009 Dec; 90(6):1525-31.
      View in: PubMed
    15. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics. 2008 Sep; 3(1):7-16.
      View in: PubMed
    16. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008 Apr; 57(4):494-501.
      View in: PubMed
    17. Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, Scherzer R, Grunfeld C. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab. 2008 Jan; 93(1):216-24.
      View in: PubMed
    18. Kosmiski LA, Bessesen DH, Stotz SA, Koeppe JR, Horton TJ. Short-term overfeeding increases resting energy expenditure in patients with HIV lipodystrophy. Am J Clin Nutr. 2007 Oct; 86(4):1009-15.
      View in: PubMed
    19. Kosmiski LA, Bessesen DH, Stotz SA, Koeppe JR, Horton TJ. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism. Metabolism. 2007 Feb; 56(2):289-95.
      View in: PubMed
    20. Koeppe J, Kosmiski L. Apparent resolution of type 2 diabetes mellitus after initiation of potent antiretroviral therapy in a man from Africa with HIV infection. Clin Infect Dis. 2006 May 15; 42(10):e79-81.
      View in: PubMed
    21. Kosmiski LA, Miller HL, Klemm DJ. In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival. Antivir Ther. 2006; 11(2):187-95.
      View in: PubMed
    22. Bush ZM, Kosmiski LA. Acute pancreatitis in HIV-infected patients: are etiologies changing since the introduction of protease inhibitor therapy? Pancreas. 2003 Jul; 27(1):e1-5.
      View in: PubMed
    23. Kosmiski LA, Kuritzkes DR, Sharp TA, Hamilton JT, Lichtenstein KA, Mosca CL, Grunwald GK, Eckel RH, Hill JO. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism. 2003 May; 52(5):620-5.
      View in: PubMed
    24. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther. 2003 Feb; 8(1):9-15.
      View in: PubMed
    25. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RH. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS. 2001 Oct 19; 15(15):1993-2000.
      View in: PubMed
    26. Donahoo WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am. 1998 Sep; 27(3):677-97.
      View in: PubMed
    Kosmiski's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
    Physical Neighbors
    _

    Copyright © 2012 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.5.1)